ArticleJournal of controlled release : official journal of the Controlled Release Society2023
STING agonist-loaded mesoporous manganese-silica nanoparticles for vaccine applications.
Open access · greenAbstract read
In one paragraph
Article in Journal of controlled release : official journal of the Controlled Release Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 47 citations in OpenAlex.
- GSH-responsive nanovaccine triggers immunogenic cell death and potent memory T cell immunity for durable, recurrence-free tumor eradication.Bioactive materials · 2026Article
- Nano-in-Micro GelMA depots assist electro-thermal-immuno orchestral treatment for solid triple negative breast tumor.Materials today. Bio · 2026Article
- Breaking barriers: The cGAS-STING pathway as a novel frontier in cancer immunotherapy.Cancer communications (London, England) · 2025Review
- Challenges and opportunities on achieving an adequate delivery efficiency and immunogenicity with peptide-based anticancer vaccines.Advanced drug delivery reviews · 2025Review
- Emerging cGAS-STING Agonist-Based Nanotherapeutics: Mechanistic Insights and Applications in Cancer Combination Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- T cells in cancer: mechanistic insights and therapeutic advances.Biomarker research · 2025Review
- Advances and Prospects of Fowl Adenoviruses Vaccine Technologies in the Past Decade.International journal of molecular sciences · 2025Review
- Advances in cancer nanovaccines: a focus on colorectal cancer.Nanomedicine (London, England) · 2025Review
- Unleashing the Potential of Metal Ions in cGAS-STING Activation: Advancing Nanomaterial-Based Tumor Immunotherapy.ACS omega · 2025Review
- Progress Update on STING Agonists as Vaccine Adjuvants.Vaccines · 2025Review
- Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer.International journal of nanomedicine · 2025Review
- Robust and Sustained STING Pathway Activation via Hydrogel-Based In Situ Vaccination for Cancer Immunotherapy.ACS nano · 2024Article
- 2D Differential Metallic Immunopotentiators Drive High Diversity and Capability of Antigen-specific Immunity Against Tumor.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Glycopolypeptide Coordinated Nanovaccine: Fabrication, Characterization, and Antitumor Immune Response.Chem & bio engineering · 2024Article
- Review
- STING agonist-conjugated metal-organic framework induces artificial leukocytoid structures and immune hotspots for systemic antitumor responses.National science review · 2024Article
- STING agonists as promising vaccine adjuvants to boost immunogenicity against SARS-related coronavirus derived infection: possible role of autophagy.Cell communication and signaling : CCS · 2024Review
- Self-Assembled STING-Activating Coordination Nanoparticles for Cancer Immunotherapy and Vaccine Applications.ACS nano · 2024Article
- Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment.Molecules (Basel, Switzerland) · 2024Review
- Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy.Biomarker research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Cheng XuDepartment of Pharmaceutical Science, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Hannah E DobsonDepartment of Pharmaceutical Science, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Mengjie YuMacromolecular Science and Engineering, University of Michigan, Ann Arbor, MI, USA.
Wang GongDepartment of Periodontics and Oral Medicine, University of Michigan, Ann Arbor, MI, USA.
Xiaoqi SunDepartment of Pharmaceutical Science, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Kyung Soo ParkBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Andrew KennedyDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, USA.
Xingwu ZhouDepartment of Pharmaceutical Science, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Jin XuDepartment of Pharmaceutical Science, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Yao XuDepartment of Pharmaceutical Science, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Andrew W TaiDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, USA.
Yu Leo LeiDepartment of Periodontics and Oral Medicine, University of Michigan, Ann Arbor, MI, USA; Department of Otolaryngology, University of Michigan, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
James J MoonDepartment of Pharmaceutical Science, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA; Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA. Electronic address: moonjj@med.umich.edu.
University of Michigan · US
Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2MRestoring the Immunogenicity of Head and Neck CancerR01DE026728 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Yu Leo Lei, James J. Moon · 2018 to 2026
$4.3MRobust Immuno-prevention Strategies for High-Risk Oral Epithelial DysplasiaU01DE029255 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BRENNER, JOHN CHADWICK, LEI, YU LEO · 2019 to 2021
$4.2MEnvironmental Regulation of Cancer Stem Cell Plasticity in MetastasisU01CA210152 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAHANN, JOERG, LUKER, GARY D · 2017 to 2021
$3.6MEngineered Nano-formulations for STING ActivationR01DE031951 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Yu Leo Lei, James J. Moon · 2022 to 2026
$3.1MNew Engineering Strategy for Harnessing Immune System against Head and Neck CancerR01DE030691 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LEI, YU LEO, MOON, JAMES J. · 2021 to 2025
$2.9MBiomaterials for modulating the gut microbiome for immune activationR01CA271799 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI James J. Moon, Deepak Nagrath · 2022 to 2026
$2.7MNovel nano-vaccine technology for inducing immunity against gliomasR01NS122536 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G, MOON, JAMES J. · 2021 to 2025
$2.6MNovel biomaterials for IBD treatmentR01DK125087 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAMADA, NOBUHIKO, MOON, JAMES J. · 2020 to 2023
$2.5MHow flaviviruses hijack a host transmembrane protein chaperone to promote viral infectionR01GM139823 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TAI, ANDREW W. · 2021 to 2024
$1.4MNCI NIH HHS P30 CA046592NCI NIH HHS R01 CA271799NCI NIH HHS U01 CA210152NIAID NIH HHS HHSN272201300006CNIDCR NIH HHS R01 DE026728NIDCR NIH HHS R01 DE030691NIDCR NIH HHS R01 DE031951NIDCR NIH HHS U01 DE029255NIDDK NIH HHS R01 DK125087NIGMS NIH HHS R01 GM139823NINDS NIH HHS R01 NS122536
Abstract
Cyclic dinucleotides (CDNs), as one type of Stimulator of Interferon Genes (STING) pathway agonist, have shown promising results for eliciting immune responses against cancer and viral infection. However, the suboptimal drug-like properties of conventional CDNs, including their short in vivo half-life and poor cellular permeability, compromise their therapeutic efficacy. In this study, we have developed a manganese-silica nanoplatform (MnO
Indexed as
COVID-19Hereditary Sensory and Motor NeuropathyNanoparticlesVaccinesAnimalsHumansImmunotherapyManganeseMiceSARS-CoV-2Silicon DioxideManganeseSilicon DioxideVaccinesImmunotherapyMesoporous silica nanoparticlesNeoantigenSTING agonistVaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.